Ciglitazone

DB09201

small molecule experimental

Deskripsi

Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.

Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.

Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPAR? ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. Ciglitazone increases adipogenesis, decreases differentiation and angiogenesis in human umbilical vein endothelial cell (HUVEC), and osteoblastogenesis in human mesenchymal stem cells.

Struktur Molekul 2D

Berat 333.45
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

828 Data
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.
Mifepristone The serum concentration of Ciglitazone can be increased when it is combined with Mifepristone.
Pregabalin The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Ciglitazone.
Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Ciglitazone.
Moxifloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Moxifloxacin.
Grepafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Grepafloxacin.
Enoxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Enoxacin.
Pefloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Pefloxacin.
Ciprofloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Ciprofloxacin.
Trovafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Trovafloxacin.
Nalidixic acid The therapeutic efficacy of Ciglitazone can be increased when used in combination with Nalidixic acid.
Rosoxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Rosoxacin.
Cinoxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Cinoxacin.
Lomefloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Lomefloxacin.
Gatifloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Gatifloxacin.
Norfloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Norfloxacin.
Levofloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Levofloxacin.
Gemifloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Gemifloxacin.
Ofloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Ofloxacin.
Sparfloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sparfloxacin.
Temafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Temafloxacin.
Fleroxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Fleroxacin.
Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
Garenoxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Garenoxacin.
Nemonoxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Nemonoxacin.
Flumequine The therapeutic efficacy of Ciglitazone can be increased when used in combination with Flumequine.
Enrofloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Enrofloxacin.
Orbifloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Orbifloxacin.
Sarafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sarafloxacin.
Difloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Difloxacin.
Pazufloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Pazufloxacin.
Prulifloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Prulifloxacin.
Delafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Delafloxacin.
Sitafloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sitafloxacin.
Oxolinic acid The therapeutic efficacy of Ciglitazone can be increased when used in combination with Oxolinic acid.
Rufloxacin The therapeutic efficacy of Ciglitazone can be increased when used in combination with Rufloxacin.
Pipemidic acid The therapeutic efficacy of Ciglitazone can be increased when used in combination with Pipemidic acid.
Methyclothiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.
Chlorthalidone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorthalidone.
Bendroflumethiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bendroflumethiazide.
Metolazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone.
Benzthiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Benzthiazide.
Hydroflumethiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydroflumethiazide.
Indapamide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Indapamide.
Chlorothiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Trichlormethiazide.
Polythiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Polythiazide.
Quinethazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quinethazone.
Cyclopenthiazide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cyclopenthiazide.
Epitizide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Epitizide.
Protriptyline Protriptyline may decrease the hypoglycemic activities of Ciglitazone.
Amoxapine Amoxapine may decrease the hypoglycemic activities of Ciglitazone.
Desipramine Desipramine may decrease the hypoglycemic activities of Ciglitazone.
Amineptine Amineptine may decrease the hypoglycemic activities of Ciglitazone.
Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Ciglitazone.
Butriptyline Butriptyline may decrease the hypoglycemic activities of Ciglitazone.
Dosulepin Dosulepin may decrease the hypoglycemic activities of Ciglitazone.
Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Ciglitazone.
Opipramol Opipramol may decrease the hypoglycemic activities of Ciglitazone.
Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Ciglitazone.
Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Ciglitazone.
Quinupramine Quinupramine may decrease the hypoglycemic activities of Ciglitazone.
Melitracen Melitracen may decrease the hypoglycemic activities of Ciglitazone.
Lofepramine Lofepramine may decrease the hypoglycemic activities of Ciglitazone.
Iprindole Iprindole may decrease the hypoglycemic activities of Ciglitazone.
Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Ciglitazone.
Imipramine Imipramine may decrease the hypoglycemic activities of Ciglitazone.
Nortriptyline Nortriptyline may decrease the hypoglycemic activities of Ciglitazone.
Trimipramine Trimipramine may decrease the hypoglycemic activities of Ciglitazone.
Doxepin Doxepin may decrease the hypoglycemic activities of Ciglitazone.
Clomipramine Clomipramine may decrease the hypoglycemic activities of Ciglitazone.
Tianeptine Tianeptine may decrease the hypoglycemic activities of Ciglitazone.
Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Ciglitazone.
Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Ciglitazone.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ciglitazone.
Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Ciglitazone.
Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Ciglitazone.
Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Ciglitazone.
Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Ciglitazone.
Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Ciglitazone.
Glisoxepide The therapeutic efficacy of Glisoxepide can be increased when used in combination with Ciglitazone.
Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Ciglitazone.
Carbutamide The therapeutic efficacy of Carbutamide can be increased when used in combination with Ciglitazone.
Metahexamide The therapeutic efficacy of Metahexamide can be increased when used in combination with Ciglitazone.
Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Ciglitazone.
Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Ciglitazone.
Canagliflozin Canagliflozin may increase the hypoglycemic activities of Ciglitazone.
Leuprolide The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.
Goserelin The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.
Ziprasidone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone.
Etonogestrel The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etonogestrel.
Desogestrel The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Desogestrel.
Olanzapine The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine.
Megestrol acetate The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Megestrol acetate.
Clozapine The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Clozapine.
Levonorgestrel The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Levonorgestrel.
Progesterone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Progesterone.
Chlorpromazine The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorpromazine.
Piperazine The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Piperazine.

Target Protein

Peroxisome proliferator-activated receptor gamma PPARG

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8505086
    Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993 Jun;21(6 Pt 2):1020-3.
  • PMID: 12372861
    Imoto H, Imamiya E, Momose Y, Sugiyama Y, Kimura H, Sohda T: Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. Chem Pharm Bull (Tokyo). 2002 Oct;50(10):1349-57.
  • PMID: 12440149
    Sohda T, Kawamatsu Y, Fujita T, Meguro K, Ikeda H: Discovery and development of a new insulin sensitizing agent, pioglitazone. Yakugaku Zasshi. 2002 Nov;122(11):909-18.
  • PMID: 19342033
    Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI: Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. Fertil Steril. 2010 Apr;93(6):2042-7. doi: 10.1016/j.fertnstert.2009.02.059. Epub 2009 Apr 1.
  • PMID: 10085162
    Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999 Mar 26;274(13):9116-21.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul